Aclarion Secures Important Coverage for Nociscan with Aviva's Support in Greater London

Aclarion's Milestone for Nociscan

Aclarion, Inc. (ACON and AIVAF), has taken a significant leap forward in the UK healthcare market by securing a second payer coverage for its flagship product, Nociscan, with Aviva, one of the UK's foremost insurance entities. This expansion into the Greater London area marks an important milestone for the company, as it aims to revolutionize the management and treatment of chronic low back pain through its innovative approach. Nociscan's technology utilizes cutting-edge biomarkers and proprietary augmented intelligence algorithms to provide physicians with an enhanced understanding of the origins of chronic low back pain, facilitating more tailored and effective treatment plans for patients.

Impact on Investment and Market Reach

The announcement of Nociscan's coverage through Aviva has not only resonated well with the healthcare community but also with investors. The inclusion of Nociscan in Aviva's coverage network signifies a robust validation of Aclarion's technology and its potential for widespread clinical adoption. This development is expected to accelerate Aclarion's penetration into the UK market, as well as enhance the company's financial performance. Both tickers, ACON and AIVAF, have received increased attention following the news, indicating a positive response from the investment community.

Aclarion, Nociscan, Aviva, Coverage, London, Healthcare, Technology, Investment, Biomarkers, AI, LowBackPain, Insurance, Market